End Stage Renal Disease. Chronic kidney disease, stage 5
Conditions
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
30 Years to 60 Years
Inclusion criteria
Inclusion criteria: Age between 30 and 60 years Undergoing regular hemodialysis (for at least the past 6 months, three sessions per week) Body mass index (BMI) greater than 18.5 and less than 30 kg/m² No hospitalization during the past 3 months Willingness to participate and cooperate in the study
Exclusion criteria
Exclusion criteria: Blood pressure higher than 160/100 mmHg Blood pressure lower than 60/100 mmHg Receiving enteral or parenteral nutritional support Use of glucocorticoids, antibiotics, Fluvoxamine, nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, or nitroglycerin Smoking History of any autoimmune diseases, thyroid disorders, malignancies, asthma, herpes, or myocardial infarction (MI) Use of antioxidant supplements within the past 3 months History of coronary artery bypass grafting (CABG) less than 12 months prior to study enrollment Kidney transplantation less than 6 months prior to study enrollment Hospitalization within the past 3 months Pregnancy, intention to become pregnant within the next 6 months, or breastfeeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum levels of Glycemic control (FBS, HbA1c, and fasting insulin). Timepoint: Before the intervention and 12 weeks later. Method of measurement: Diagnostic kits.;Insulin resistance indices (HOMA-IR, HOMA-beta, TyG, QUICKI). Timepoint: Before the intervention and 12 weeks later. Method of measurement: Calculated using the relevant formula. | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum levels of lipid parameters (T.G, T.C, LDL, HDL). Timepoint: Before the intervention and 12 weeks later. Method of measurement: spectrophotometry method.;Serum levels of oxidative stress markers (TAC, MDA). Timepoint: Before the intervention and 12 weeks later. Method of measurement: spectrophotometry method.;Fatigue status. Timepoint: Before the intervention and 12 weeks later. Method of measurement: Completion of the Fatigue Assessment Scale (FAS) questionnaire.;Systolic and diastolic blood pressure. Timepoint: Before the intervention and 12 weeks later. Method of measurement: Sphygmomanometer and calibrated stethoscope.;Anthropometric indices (body weight, body mass index, skeletal muscle mass index, fat mass, extracellular water to total body water ratio, and phase angle). Timepoint: Before the intervention and 12 weeks later. Method of measurement: Anea BIA 1204 body composition analysis. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHossein Imani
Tehran University of Medical Sciences
Outcome results
None listed